Lixte Biotechnology Holdings, INC Form 4 insider transactions
NASDAQ
Director Rene Bernards acquired 5,304 shares of LIXTE Biotechnology Holdings, Inc. through stock options in lieu of quarterly cash compensation.
NASDAQ
Director Stephen J. Forman reports acquisition of Lixte Biotechnology Holdings shares through stock options in lieu of quarterly cash compensation.
NASDAQ
Director Regina Brown reports the acquisition of stock options in Lixte Biotechnology Holdings, Inc. in lieu of quarterly cash compensation.
NASDAQ
Form 4: Lixte Biotechnology Director Yun Yen Reports Stock Option Grant in Lieu of Cash Compensation
Director Yun Yen reports receiving stock options for 5,786 shares of Lixte Biotechnology in lieu of quarterly cash compensation on September 30, 2024.
NASDAQ
Form 4: Lixte Biotechnology Director Rene Bernards Receives Stock Options in Lieu of Cash Compensation
Director Rene Bernards received stock options from Lixte Biotechnology Holdings, Inc. in lieu of cash compensation, according to a Form 4 filing.
NASDAQ
Director Yun Yen reports the acquisition of stock options in Lixte Biotechnology Holdings, Inc.
NASDAQ
Director Stephen Forman reports the grant of stock options in Lixte Biotechnology Holdings, Inc.
NASDAQ
Regina Brown, a director of Lixte Biotechnology Holdings, Inc., reported the acquisition of stock options on June 30, 2024.